Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence

References

• Canadian Psychiatric AssociationClinical practice guidelines. Treatment of schizophreniaCan J Psychiatry200550Suppl 1757
   Google Scholar
• HaroJMNovickDSuarezDRocaMAntipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO studyJ Psychiatr Res20094326527318644606
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• ValensteinMCopelandLABlowFCPharmacy data identify poorly adherent patients with schizophrenia at increased risk for admissionMedical Care20024063063912187177
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv20045588689115292538
   PubMed Web of Science ®Google Scholar
• SvarstadBLShiremanTISweeneyJKUsing drug claims data to assess the relationship of medication adherence with hospitalization and costsPsychiatr Serv20015280581111376229
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDLandbloomRSwartzMSwansonJTime to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaBMC Psychiatry20066816504026
   PubMed Web of Science ®Google Scholar
• DunayevichEAscher-SvanumHZhaoFLonger time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorderJ Clin Psychiatry2007681163117117854239
   PubMed Web of Science ®Google Scholar
• CorriganPWLibermanRPEngelJDFrom noncompliance to collaboration in the treatment of schizophreniaHosp Community Psychiatry199041120312111979044
   PubMedGoogle Scholar
• MasandPSRocaMTurnerMSKaneJMPartial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a reviewPrim Care Companion J Clin Psychiatry20091114715419750066
   PubMedGoogle Scholar
• StroupTSMcEvoyJPSwartzMSThe National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developmentSchizophr Bull200329153112908658
   PubMed Web of Science ®Google Scholar
• ChenLMcCombsJSParkJDuration of antipsychotic drug therapy in real-world practice: a comparison with CATIE trial resultsValue Health20081148749618489672
   PubMed Web of Science ®Google Scholar
• HaroJMNovickDBelgerMJonesPBAntipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophreniaEur Psychiatry200621414716414249
   PubMed Web of Science ®Google Scholar
• KilziehNTodd-StenbergJAKennedyAWoodAETappAMTime to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient settingJ Clin Psychopharmacol200828747718204345
   PubMed Web of Science ®Google Scholar
• MullinsCDObeidatNACuffelBJNaradzayJLoebelADRisk of discontinuation of atypical antipsychotic agents in the treatment of schizophreniaSchizophr Res20089881517596914
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDELacroJPDolderCRPengXAdherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophreniaPatient Prefer Adherence20082677719920946
   PubMedGoogle Scholar
• DossenbachMArango-DávilaCSilva IbarraHResponse and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) studyJ Clin Psychiatry2005661021103016086618
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDLacroJPDolderCRA prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophreniaJ Clin Psychiatry2006671114112316889456
   PubMed Web of Science ®Google Scholar
• LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry20026389290912416599
   PubMed Web of Science ®Google Scholar
• KelinKBrnabicAJMNewtonRBaseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherencePat Pref Adherence20104301311
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA)Diagnostic and statistical manual of mental disorders (DSM-IV)Washington DCAmerican Psychiatric Association1994
   Google Scholar
• GuyWECDEU assessment manual for psychopharmacologyRockville, MDUS Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs1976
   Google Scholar
• HoganTPAwadAGEastwoodRA self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validityPsychol Med1983131771836133297
   PubMed Web of Science ®Google Scholar
• The EuroQol Group: EuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy19901619920810109801
   PubMed Web of Science ®Google Scholar
• WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care1992304734831593914
   PubMed Web of Science ®Google Scholar
• DolanPModeling valuations for EuroQol health statesMed Care199735109511089366889
   PubMed Web of Science ®Google Scholar
• KaragianisJWilliamsRDavisLAntipsychotic switching: results from a one-year prospective, observational study of patients with schizophreniaCurr Med Res Opin2009252121213219601707
   PubMed Web of Science ®Google Scholar
• SerrettiADe RonchiDLorenziCBerardiDNew antipsychotics and schizophrenia: a review on efficacy and side effectsCurr Med Chem20041134335814965236
   PubMed Web of Science ®Google Scholar
• TiihonenJWahlbeckKLönnqvistJEffectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up studyBMJ200633322416825203
   PubMed Web of Science ®Google Scholar
• ZhuBAscher-SvanumHShiLFariesDMontgomeryWMarderSRTime to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophreniaPsychiatr Serv20085931531718308914
   PubMed Web of Science ®Google Scholar
• HeresSSchmitzFSLeuchtSPajonkFGThe attitude of patients towards antipsychotic depot treatmentInt Clin Psychopharmacol20072227528217690596
   PubMed Web of Science ®Google Scholar
• PatelMXde ZoysaNBernadtMDavidASA cross-sectional study of patients’ perspectives on adherence to antipsychotic medication: depot versus oralJ Clin Psychiatry2008691548155619192437
   PubMed Web of Science ®Google Scholar
• HeresSHamannJKisslingWLeuchtSAttitudes of psychiatrists toward antipsychotic depot medicationJ Clin Psychiatry2006671948195317194274
   PubMed Web of Science ®Google Scholar
• HamannJMendelRHeresSLeuchtSKisslingWHow much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribedEur Neuropsychopharmacol20102027627920133108
   PubMed Web of Science ®Google Scholar
• ChongMYTanCHFujiiSAntipsychotic drug prescription for schizophrenia in East Asia: rationale for changePsychiatry Clin Neurosci200458616714678459
   PubMed Web of Science ®Google Scholar
• YangYKTarnYHWangTYPharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costsPsychiatry Clin Neurosci20055938539416048443
   PubMed Web of Science ®Google Scholar
• WeidenPJUnderstanding and addressing adherence issues in schizophrenia: from theory to practiceJ Clin Psychiatry200768Suppl 141419
   Google Scholar
• VelliganDILamYWGlahnDCDefining and assessing adherence to oral antipsychotics: a review of the literatureSchizophr Bull20063272474216707778
   PubMed Web of Science ®Google Scholar
• BarbuiCKikkertMMazziMAComparison of patient and clinician perspectives in the assessment of antipsychotic medication adherencePsychopathology20094231131719672133
   PubMed Web of Science ®Google Scholar
• CooperDMoisanJGrégoireJPAdherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophreniaJ Clin Psychiatry20076881882517592904
   PubMed Web of Science ®Google Scholar
• ByerlyMFisherRWhatleyKA comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophreniaPsychiatry Res200513312913315740989
   PubMed Web of Science ®Google Scholar
• NoséMBarbuiCTansellaMHow often do patients with psychosis fail to adhere to treatment programmes? A systematic reviewPsychol Med2003331149116014580069
   PubMed Web of Science ®Google Scholar
• BitterITreuerTDyachkovaYMartenyiFMcBrideMUngvariGSAntipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) studyEur Neuropsychopharmacol20081817018017884390
   PubMed Web of Science ®Google Scholar